Bromocriptine Administration Reduces Hyperphagia and Adiposity and Differentially Affects Dopamine D2 Receptor and Transporter Binding in Leptin-Receptor-Deficient Zucker Rats and Rats with Diet-Induced Obesity

BACKGROUND: The dopamine (DA) D(2) receptor (D2R) agonist bromocriptine (BC) decreases body fat in animal and human models and increases lean muscle mass, improves glucose intolerance and insulin resistance, and reduces triglycerides and free fatty acids. We have previously shown a negative correlat...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Päätekijät: Davis, Lisa M., Michaelides, Michael, Cheskin, Lawrence J., Moran, Timothy H., Aja, Susan, Watkins, Paul A., Pei, Zhengtong, Contoreggi, Carlo, McCullough, Karen, Hope, Bruce, Wang, Gene Jack, Volkow, Nora D., Thanos, Panayotis K.
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: 2008
Aiheet:
Article
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC2681080/
https://ncbi.nlm.nih.gov/pubmed/18984941
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1159/000170586
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia